BeiGene CEO John Oyler at an Endpoints News/PharmCube event in Shanghai, October 2018 (Credit: Endpoints News)

Am­gen takes a $2.7B stake in BeiGene, gain­ing a promi­nent al­ly in Chi­na to help seize a lead­ing role in can­cer drug com­mer­cial­iza­tion and de­vel­op­ment

Am­gen has found both a com­mer­cial part­ner to help build up its can­cer drug rev­enue in Chi­na, as well as a fast grow­ing R&D part­ner …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.